Autopsy report · NCT03339999

AGN-242428 in the Treatment of Plaque Psoriasis

“safety reason”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 months before it stopped.
• 24 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Vitae Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Plaque Psoriasis

Interventions

AGN-242428; Placebo

Participants

24

Sites

15

Countries

United States

Trials that died the same way

• Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis
  “For safety concerns” (81% match in meaning)
• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (77% match in meaning)
• Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
  “Safety-related” (75% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (73% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.